ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lantheus Medical Imaging has received U.S. approvals to use molybdenum-99 from the Nuclear Research Institute in Rez, Czech Republic, to produce medical isotopes. Mo-99, used to generate technetium-99m for imaging procedures, has been scarce while nuclear reactors in Canada and the Netherlands undergo repairs. Separately, PerkinElmer says it is the first firm to offer current Good Manufacturing Practice-compliant lutetium-177 nuclide. The new product, which can be used in the development of various cancer treatments, is the result of an agreement between PerkinElmer and the University of Missouri Research Reactor.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X